Mark Kipnes
5 Papers
25 Citations
Mark Kipnes is an academic researcher. The author has contributed to research in topics: Nonalcoholic fatty liver disease & Randomized controlled trial. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Sunder Mudaliar,Robert R. Henry,Arun J. Sanyal,Linda Morrow,Hanns-Ulrich Marschall,Mark Kipnes,Luciano Adorini,Cathi Sciacca,Paul Clopton,E. Castelloe,Paul Dillon,Mark Pruzanski,David Shapiro +12 more
TL;DR: Administration of 25 or 50 mg OCA for 6 weeks was well tolerated, increased insulin sensitivity, and reduced markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.
918
M1254 Safety and Functionality of Gastric Electrical Stimulation with TANTALUS® On Glycemic Control in Overweight Subjects with Type 2 Diabetes - Results of a Clinical Feasibility Study On An Investigational Device
Claudia P. Sanmiguel,Jeffrey L. Conklin,Mark Kipnes,John Pilcher,Scott A. Cunneen,Philip Barnett,Edward H. Phillips,Edy E. Soffer +7 more
1
Safety and effectiveness of REALIZE adjustable gastric band: 5-year prospective study
Edward M. Phillips,Jaime Ponce,Sunil Bhoyrul,Scott A. Cunneen,Eddie Gomez,Moises Jacobs,Mark Kipnes,Robert T. Marema,Michael Schwiers,Jason R. Waggoner,Janet DeMarchi +10 more
TL;DR: In this paper, the long-term safety results of the REALIZE adjustable gastric band collected in this prospective, multicenter study in patients with morbid obesity are presented, including the reoperation rate, including band revisions, replacements, and explants, resulting from a serious adverse device-related event through years 4 and 5.
1
Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial
David Silvers,Mark Kipnes,Vasti L. Broadstone,David R. Patterson,Eamonn Martin Quigley,Richard W. McCallum,Nancy Kline Leidy,Christina Farup,Yin Liu,Alan Joslyn +9 more
TL;DR: The results of this study suggest that domperidone 20 mg QID provides significant improvement in the upper gastrointestinal symptoms of diabetic gastroparesis and is well tolerated in patients with this condition.